Mark C. McKenna, a director at $APGE ($APGE), bought 12,500 shares of the company on 12-12-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their...
Apogee Therapeutics initiates Phase 1 trial for APG333 targeting respiratory diseases, with interim data expected in 2025.Quiver AI SummaryApogee Therapeutics has initiated a Phase 1 clinical trial for...
Carl Dambkowski, the Chief Medical Officer of $APGE ($APGE), sold 6,665 shares of the company on 12-04-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 2.5%...
Apogee Therapeutics announced positive Phase 1 data for APG808 and APG777, highlighting potential for prolonged dosing in inflammatory diseases.Quiver AI SummaryApogee Therapeutics reported positive interim...
Apogee Therapeutics announces virtual R&D Day agenda focusing on novel biologics for inflammatory and immunology conditions.Quiver AI SummaryApogee Therapeutics, Inc. has announced its agenda for a virtual...
Apogee Therapeutics will host a virtual R&D Day on December 2, 2024, discussing its innovative programs and strategies.Quiver AI SummaryApogee Therapeutics, Inc., a clinical-stage biotechnology company...